Dr. Reddy's Laboratories launches Cinacalcet Tablets in US market
1 October 2020 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Thursday announced the availability of its US Food and Drug Administration (FDA) approved Cinacalcet Tablets in the United States.

Dr. Reddy's Cinacalcet Tablets are a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets. The Sensipar brand and generic market had US sales of approximately USD312m MAT for the 12 months ending in July 2020, according to IQVIA Health.

Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg tablets in a bottle count size of 30.

Cinacalcet is a medication used to treat secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism.